2021
Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System
Patel T, Miccio J, Cecchini M, Srikumar T, Stein S, Kortmanksy J, Johung K, Lacy J. Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System. Journal Of Gastrointestinal Oncology 2021, 0: 0-0. PMID: 35070386, PMCID: PMC8748034, DOI: 10.21037/jgo-21-202.Peer-Reviewed Original ResearchMetastatic pancreatic cancerFirst-line FOLFIRINOXTreatment discontinuationFFX groupDose modificationOverall survivalNab-paclitaxelPancreatic cancerGN groupComparative effectivenessMedian TTDFirst-line settingMedian overall survivalOutcomes of patientsTreatment-related toxicityFirst-line therapyKaplan-Meier methodRate of hospitalizationElectronic medical record systemAdjuvant gemcitabineChemotherapy toxicityDiscontinuation ratesLine therapyMedical record systemTreatment toxicity
2017
EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.
Cecchini M, Sklar J, Lacy J. EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance. Journal Of The National Comprehensive Cancer Network 2017, 15: 1085-1089. PMID: 28874593, DOI: 10.6004/jnccn.2017.0151.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaTyrosine kinase inhibitorsMetastatic pancreatic ductal adenocarcinomaEGFR Exon 19 DeletionEGFR tyrosine kinase inhibitorsImmune checkpoint inhibitorsMetastatic pancreatic cancerExon 19 deletionsEpidermal growth factor receptorGrowth factor receptorAdvanced diseaseCheckpoint inhibitorsMultidrug chemotherapyPancreatic cancerDisease progressionDuctal adenocarcinomaPancreatic adenocarcinomaActionable mutationsTumor typesKinase inhibitorsExon 19Factor receptorAdenocarcinomaPatientsErlotinib